NC-2500

NC-2500 is a novel advanced xanthine oxidoreductase (XOR) inhibitor, having potential to reduce the risk of gout flare, one of major issues of current treatments for gout, and make a difference in gout treatment.
In the Phase-1 study, NC-2500 showed favorable urate-lowering properties, that is NC-2500 lowered serum urate levels gradually to the same extent as current XOR inhibitors through 7 days, which could decrease the risk of acute flare in gout patients. Acute flare due to rapid urate reduction is one of the major issues in the initial phase of current therapy, which impairs patients’ quality of life and adherence, frequently resulting in failing sufficient control of serum urate and then worsening the disease. NC-2500 is expected to have potential to resolve these issues by its unique profile of reducing urate to avoid acute flare, with no need of or minimal titration. As for safety, NC-2500 was well-tolerated and adverse events were infrequent, transient, mild, and comparable to placebo. Furthermore, NC-2500 was hardly excreted through the renal pathway, which can be a favorite profile for patients with renal impairment, frequently observed in gout.

NC-2700

NC-2700 is a novel urate transporter 1 (URAT1) inhibitor, enhancing excretion urate to urine. NC-2700 showed not just a potent uricosuric effect, but also pH-raising of the urine with lowered pH in an animal model, which could decrease the risk of renal calculus and nephrotoxicity with urate crystal in the urine, the most common issue with current uricosuric therapy. NC-2700 is now ready to start a phase-1 clinical study.

Business Development
We are interested in any opportunities of collaboration, partnering or licensing of our pipeline products and welcome any proposal on them. If you have any interest in any of our pipeline products, please contact our business development team bd@chemiphar.co.jp.
Related Information

Business Development Contact

If you have any interest in our pipeline, please contact our business development team bd@chemiphar.co.jp.

Get ADOBE® READER®

NOTICE
To view our PDF files, you need Adobe Reader software installed on your local drive. The Adobe Reader can be downloaded by clicking on this icon.

PageTop